IP Library › Granted Patent US 7,034,054
Granted Patent B2
US 7,034,054 · App. 10/020,450 · Granted Apr 25, 2006

Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,034,054
App. No.
10/020,450
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention provides method for the treatment of a symptom of neuronal damage associated with cerebral ischemia comprising administering gamma-, beta-, or delta-tocopherol enriched tocopherol compositions.

Claims (43)

1. A method for treating and/or ameliorating a symptom of neuronal damage associated with a cerebral ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a non-alpha tocopherol enriched tocopherol composition, and by said administering, reducing neuronal damage related to said cerebral ischemic condition.

2. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a gamma-tocopherol enriched tocopherol composition.

3. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a beta-tocopherol enriched tocopherol composition.

4. The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a delta-tocopherol enriched tocopherol composition.

5. The method of claim 1 wherein the cerebral ischemic condition is secondary to an occlusion of the cerebral vasculature.

6. The method of claim 5 wherein the occlusion is due to a thromboembolus.

7. The method of claim 1 wherein the cerebral ischemia is due to a spasm of the coronary vasculature.

8. The method of claim 1 wherein the cerebral ischemic condition is secondary to a cessation of cardiac function.

9. The method of claim 1 wherein the cerebral ischemic condition is secondary to a cardiopulmonary bypass procedure.

10. The method of claim 1 wherein the cerebral ischemic condition is secondary to a hemorrhagic event in the cerebral vasculature.

11. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 60% gamma-tocopherol.

12. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 65% gamma-tocopherol.

13. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 70% ma-tocopherol.

14. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 75% gamma-tocopherol.

15. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 80% gamma-tocopherol.

16. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 85% gamma-tocopherol.

17. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 90% gamma-tocopherol.

18. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 95% gamma-tocopherol.

19. The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 98% gamma-tocopherol.

20. The method of claim 3 herein said beta-tocopherol enriched tocopherol composition comprises at least 50% beta-tocopherol.

21. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 65% be-tocopherol.

22. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 75% beta-tocopherol.

23. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 90% beta-tocopherol.

24. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 95% beta-tocopherol.

25. The method of claim 3 wherein said beta-tocopherol enriched tocopherol composition comprises at least 98% beta-tocopherol.

26. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 50% delta-tocopherol.

27. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 65% delta-tocopherol.

28. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 75% delta-tocopherol.

29. The method of claim wherein said delta-tocopherol enriched tocopherol composition comprises at least 90%/o delta-tocopherol.

30. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 95% delta-tocopherol.

31. The method of claim 4 wherein said delta-tocopherol enriched tocopherol composition comprises at least 98% delta-tocopherol.

32. The method of claim 1 wherein said composition is a nutritional composition.

33. The method of claim 1 wherein said composition is a pharmaceutical composition.

34. The method of claim 1 wherein said composition is administered orally.

35. The method of claim 1 wherein said composition is administered parenterally.

36. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-1000 mg per kg body weight of said mammalian subject.

37. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-50 mg per kg body weight of said mammalian subject.

38. The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 10-100 mg per kg body weight of said mammalian subject.

39. The method of claim 1 , wherein said neuronal damage is neuronal cell death.

40. The method of claim 1 , wherein said neuronal damage is total cerebral infarct volume.

41. The method of claim 1 , wherein said neuronal damage is total cerebral ischemic damage.

42. The method of claim 1 , wherein said neuronal damage is cerebral tissue edema.

43. The method of claim 1 , wherein said neuronal damage is cognitive dysfunction.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2019
From: BIOELECTRON TECHNOLOGY CORPORATION
To: PTC THERAPEUTICS, INC.
Reel/Frame 051041/0478 →
CHANGE OF NAME Recorded Feb 8, 2017
From: EDISON PHARMACEUTICALS, INC.
To: BIOELECTRON TECHNOLOGY CORPORATION
Reel/Frame 041660/0644 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2017
From: AMPERE LIFE SCIENCES, INC.
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 041197/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2012
From: EDISON PHARMACEUTICALS, INC.
To: AMPERE LIFE SCIENCES, INC.
Reel/Frame 027792/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2007
From: GALILEO PHARMACEUTICALS, INC.
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 019287/0820 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2007
From: ALLOY VENTURES, INC. AS SECURED PARTY AND AS COLLATERAL AGENT FOR ADDITIONAL SECURED PARTIES UNDER THE SECURED NOTE PURCHASE AGREEMENT DATED AS OF DECEMBER 22, 2005
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 019009/0088 →
SECURITY AGREEMENT Recorded Dec 22, 2005
From: GALILEO PHARMACEUTICALS, INC.
To: ALLOY VENTURES, INC.
Reel/Frame 016936/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2004
From: KHANSARI, PARTO
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 014303/0513 →
CHANGE OF NAME Recorded Jul 15, 2003
From: GALILEO LABORTORIES, INC.
To: GALILEO PHARMACEUTICALS, INC.
Reel/Frame 013805/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2002
From: MILLER, GUY MICHAEL; BROWN, LESLEY A.; DEL BALZO, UGHETTA; FLAIM, STEPHEN; BODDUPALLI, SEKHAR; WANG, BING
To: GALILEO LABORATORIES, INC.
Reel/Frame 012736/0550 →